Selective Optimization of Side Activities (SOSA) as an Efficient Approach for Generation of New Leads from Old Drugs

Preeti P. Mehta *

Department of Pharmaceutical Chemistry, School of Pharmacy, Vishwakarma University, Pune-411048, India.

Yogita Ozarde

Department of Pharmaceutical Chemistry, Dr. Vishwanath Karad MIT World Peace University School of Pharmacy, Pune-411038, India.

Ranjit Gadhave

Department of Pharmaceutical Chemistry, Dr. Vishwanath Karad MIT World Peace University School of Pharmacy, Pune-411038, India.

Arti Swami

Department of Pharmaceutical Chemistry, Dr. Vishwanath Karad MIT World Peace University School of Pharmacy, Pune-411038, India.

*Author to whom correspondence should be addressed.


Abstract

The selective optimization of side activities (SOSA) approach appears to be a promising strategy for lead generation. In this approach old drugs are used to generate new hits or leads. The objective of SOSA is to prepare analogues of the hit molecule in order to transform the observed “side activity” into the main effect and to strongly reduce or abolish the initial pharmacological activity. The idea of taking a molecule with a primary activity in humans and then enhancing a secondary effect through structural changes describes the most common implementation of SOSA. An advantage to starting a drug discovery program with molecules that have already been tested in humans is that those molecules have already satisfied many safety criteria. Such molecules also likely have favourable pharmacokinetic profiles. In the present review different successful examples of SOSA switches are summarized. We hope that the present review will be useful for scientists working in the area of drug design and discovery.

Keywords: SOSA, selective optimization of side activities, drug discovery, hit to lead, lead generation


How to Cite

Mehta, P. P., Ozarde, Y., Gadhave, R. and Swami, A. (2021) “Selective Optimization of Side Activities (SOSA) as an Efficient Approach for Generation of New Leads from Old Drugs”, Journal of Pharmaceutical Research International, 33(42B), pp. 287–297. doi: 10.9734/jpri/2021/v33i42B32447.